Literature DB >> 11227213

Endothelial cell survival and apoptosis in the tumor vasculature.

W Liu1, S A Ahmad, N Reinmuth, R M Shaheen, Y D Jung, F Fan, L M Ellis.   

Abstract

Angiogenesis is essential for the growth and metastasis of solid tumors. The balance of endothelial cell (EC) proliferation and apoptosis is a major determinant in tumor angiogenesis. Recently, several studies demonstrated that numerous angiogenic factors not only induce angiogenesis but also function as EC survival factors. Vascular endothelial growth factor (VEGF), a potent angiogenic factor, is also an EC survival factor in embryonic vasculogenesis and tumor angiogenesis. VEGF activates specific intracellular survival pathways in ECs including Bcl-2, A1, IAP, Akt, and Erk. Integrins may function as EC survival factors by preventing anoikis by enhancing binding to the extracellular matrix. In addition, integrins may function in concert with VEGF to promote EC survival. Angiopoietin-1 (Ang-1) has recently been shown to stabilize EC networks by binding to the EC-specific tyrosine kinase receptor Tie-2. Pericytes also function as EC survival factors, by cell-cell contact, secretion of survival factors, or both. Targeting any of the above mechanisms for EC survival may provide novel antineoplastic strategies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11227213     DOI: 10.1023/a:1009679307513

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  28 in total

1.  Microvascular patterning is controlled by fine-tuning the Akt signal.

Authors:  Jing Fang Sun; Thuy Phung; Ichiro Shiojima; Terri Felske; J Nalinee Upalakalin; Dian Feng; Tad Kornaga; Talia Dor; Ann M Dvorak; Kenneth Walsh; Laura E Benjamin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-20       Impact factor: 11.205

2.  Recombinant vascular basement-membrane-derived multifunctional peptide inhibits angiogenesis and growth of hepatocellular carcinoma.

Authors:  You-Hua Wu; Jian-Guo Cao; Hong-Lin Xiang; Hong Xia; Yong Qin; A-Ji Huang; Di Xiao; Fang Xu
Journal:  World J Gastroenterol       Date:  2009-04-14       Impact factor: 5.742

3.  Angiogenesis and melanoma - from basic science to clinical trials.

Authors:  Maxine Sylvia Emmett; Daemon Dewing; Rowan Oliver Pritchard-Jones
Journal:  Am J Cancer Res       Date:  2011-08-08       Impact factor: 6.166

4.  Computational modelling of anti-angiogenic therapies based on multiparametric molecular imaging data.

Authors:  Benjamin Titz; Kevin R Kozak; Robert Jeraj
Journal:  Phys Med Biol       Date:  2012-09-13       Impact factor: 3.609

5.  Histone deacetylase inhibitors enhance endothelial cell sprouting angiogenesis in vitro.

Authors:  Guang Jin; Dirk Bausch; Thomas Knightly; Zhengcai Liu; Yongqing Li; Baoling Liu; Jennifer Lu; Wei Chong; George C Velmahos; Hasan B Alam
Journal:  Surgery       Date:  2011-09       Impact factor: 3.982

Review 6.  Mechanisms of radiation-induced brain toxicity and implications for future clinical trials.

Authors:  Jae Ho Kim; Stephen L Brown; Kenneth A Jenrow; Samuel Ryu
Journal:  J Neurooncol       Date:  2008-01-22       Impact factor: 4.130

7.  Pericyte-mediated regulation of capillary diameter: a component of neurovascular coupling in health and disease.

Authors:  Nicola B Hamilton; David Attwell; Catherine N Hall
Journal:  Front Neuroenergetics       Date:  2010-05-21

8.  Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors.

Authors:  Peter Baluk; Shunichi Morikawa; Amy Haskell; Michael Mancuso; Donald M McDonald
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

9.  HoxA5 stabilizes adherens junctions via increased Akt1.

Authors:  Gemma Arderiu; Ileana Cuevas; Amy Chen; Meritxell Carrio; Lucy East; Nancy J Boudreau
Journal:  Cell Adh Migr       Date:  2007-10-20       Impact factor: 3.405

10.  Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma.

Authors:  Faruk Tas; Derya Duranyildiz; Hilal Oguz; Hakan Camlica; Vildan Yasasever; Erkan Topuz
Journal:  Med Oncol       Date:  2008-03-25       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.